What You Should Know:
– KPMG offers its data & analytics capabilities to address emerging challenges tied to matching recovered patients with those in clinical trials to receive convalescent plasma.
– KPMG’s capabilities can make the plasma donation process easier and more efficient by automating the complex tasks and logistics associated with the data collection, qualification and matching process by performing statistical analytics, and using artificial intelligence (AI), virtualized data, and blockchain to trace the plasma from donor to clinical trial patient.
Recognizing the need for technologies to help advance the response and recovery to the COVID-19 pandemic, KPMG LLP has built the technology architecture for a solution that can match patients in clinical trials for convalescent plasma therapy to recovered patients willing to donate their antibodies.
Simplifying The Plasma Donation Process
Data & analytics can simplify the process of matching patients who have recovered with patients that are undergoing clinical trials. According to media reports, the FDA paused the use of convalescent plasma therapy for emergency cases, citing inconclusive data. A federal registry for clinical trials lists 54 U.S. studies of convalescent plasma therapy for treating COVID-19, with a majority of them still recruiting patients.
KPMG’s capabilities can make the plasma donation process easier and more efficient by automating the complex tasks and logistics associated with the data collection, qualification and matching process by performing statistical analytics, and using artificial intelligence (AI), virtualized data, and blockchain to trace the plasma from donor to clinical trial patient. KPMG’s framework is designed to integrate third-party data from blood banks, hospitals, and diagnostic labs and work with data backbones and existing technology applications that are already in place, such as IT infrastructure owned by governments and hospitals.
The technology can also be deployed for contact tracing or monitoring vaccine use to help policy makers with population health and social distancing decisions. KPMG introduced this technology as part of its recently announced “Restarting America” initiative to help organizations safely reopen workplaces.
“This solution is designed to help ease the burden on plasma donors, accelerate the COVID-19 plasma donation process and provide better visibility to health authorities, while helping facilitate the study of convalescent plasma,” said Bharat Rao, PhD, principal and leader of Data and Analytics for healthcare & life sciences at KPMG. “With the use of a mobile app, the data is better organized in a secure format, and reduces the duplication of requests and administrative overhead among healthcare organizations.”
